{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:12:32Z","timestamp":1769087552167,"version":"3.49.0"},"reference-count":54,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pomeranian Medical University in Szczecin","award":["WNoZ-322-01\/S\/19\/2024"],"award-info":[{"award-number":["WNoZ-322-01\/S\/19\/2024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Currently, it is a priority to develop prognostic biomarkers that would allow the identification of patients with progressing prostate diseases with a low risk of progression, so that unnecessary treatment and patient burden can be avoided. Objectives: This study aimed to assess the clinical features and concentrations of selected mediators of apoptosis, markers of inflammation, and immunoexpression of Ki67 and selected mediators of inflammation in patients with PCa after prostatectomy procedures and who underwent palliative radiotherapy for bone metastases, as well as patients with benign prostatic hyperplasia (BPH). Methods: A total of 88 patients, including 54 cases with PCa and 34 with BPH, were included. Stage and tumor grades were determined according to Gleason\u2019s grading system. Immunoenzymatic methods were used to determine apoptotic and inflammatory mediators in serum, as well as deoxynucleotidyl transferase-mediated dUTP Nick End Labeling (TUNEL) reaction, and immunohistochemistry to determine selected markers of inflammation and Ki67 expression. Results: Strong differentiating indicators were revealed, such as Ki67, and tumor necrosis factor receptor 2. Ki-67 expression was significantly associated with the Gleason score. In turn, the tumor necrosis factor receptor 2 (TNFRII) showed the highest expression in the inflammatory environment of cancer in the metastatic stage. Conclusions: Ki67 and TNFRII can be classified as high-value clinical markers. These factors may be treated as markers regarding future information about the implementation or withdrawal of more aggressive treatment to possibly avoid toxic complications associated with both increased doses in radiotherapy and prolonged hormonal therapy.<\/jats:p>","DOI":"10.3390\/cancers17162638","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T07:45:31Z","timestamp":1755071131000},"page":"2638","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ki67 and TNFRII as Potential Clinical Markers for Effective Clinical Staging of Advanced Prostate Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9592-6433","authenticated-orcid":false,"given":"Edyta Idalia","family":"Wolny-Rokicka","sequence":"first","affiliation":[{"name":"Department of Histology and Developmental Biology, Faculty of Health Sciences, Pomeranian Medical University, \u017bo\u0142nierska 48, 71-210 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-0738","authenticated-orcid":false,"given":"Marta","family":"Grabowska","sequence":"additional","affiliation":[{"name":"Department of Histology and Developmental Biology, Faculty of Health Sciences, Pomeranian Medical University, \u017bo\u0142nierska 48, 71-210 Szczecin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"ref_1","first-page":"e48252","article-title":"An In-Depth Look Into the Epidemiological and Etiological Aspects of Prostate Cancer: A Literature Review","volume":"15","author":"Salameh","year":"2023","journal-title":"Cureus"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., and Du, L. (2022). Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.811044"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/PAS.0000000000000736","article-title":"Histologic grading of prostatic adenocarcinoma can be further optimized: Analysis of the relative prognostic strength of individual architectural patterns in 1275 patients from the Canary retrospective cohort","volume":"40","author":"McKenney","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.2147\/CMAR.S250829","article-title":"Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review","volume":"12","author":"McNally","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/pcan.2010.36","article-title":"Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance","volume":"14","author":"Kotb","year":"2011","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7150\/jca.1.150","article-title":"Novel diagnostic biomarkers for prostate cancer","volume":"1","author":"Madu","year":"2010","journal-title":"J. Cancer"},{"key":"ref_8","first-page":"e925860","article-title":"Analysis of Serum Markers with Regard to Treatment Procedures in Advanced Stage Prostate Cancer Patients","volume":"26","author":"Petrasz","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","article-title":"Ki-67: More than a proliferation marker","volume":"127","author":"Sun","year":"2018","journal-title":"Chromosoma"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/PAT.0000000000000320","article-title":"Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer","volume":"47","author":"Goltz","year":"2015","journal-title":"Pathology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2013.01.016","article-title":"Ki-67 Is an Independent Predictor of Metastasis and Cause-Specific Mortality for Prostate Cancer Patients Treated on Radiation Therapy Oncology Group (RTOG) 94\u201308","volume":"86","author":"Verhoven","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Byun, S.S., Lee, M., Hong, S.K., and Lee, H. (2019). Elevated Ki-67 (MIB-1) expression as an independent predictor for unfavorable pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with localized prostate cancer: A propensity score matched study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224671"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/j.clbc.2022.02.001","article-title":"Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated With Trimodality Therapy","volume":"22","author":"Song","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","article-title":"Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67","volume":"133","author":"Gerdes","year":"1984","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clbc.2014.12.007","article-title":"High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients with Estrogen Receptor-Positive and HER2-Negative Breast Cancer","volume":"15","author":"Nishimukai","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","article-title":"Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry","volume":"139","author":"Inwald","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/bjc.2014.402","article-title":"Tumour cell proliferation (Ki-67) in non-small cell lung cancer: A critical reappraisal of its prognostic role","volume":"111","author":"Warth","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4103\/0974-7796.158507","article-title":"Significance of p53 and ki-67 expression in prostate cancer","volume":"7","author":"Verma","year":"2015","journal-title":"Urol. Ann."},{"key":"ref_19","first-page":"12","article-title":"Evaluation of minimal prostate cancer in needle biopsy specimens using AMACR (p504s), p63 and Ki-67","volume":"9","author":"Rashed","year":"2012","journal-title":"Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2004.09.150","article-title":"Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02","volume":"22","author":"Pollack","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"717080","DOI":"10.1155\/2013\/717080","article-title":"Quantifying the ki-67 heterogeneity profile in prostate cancer","volume":"2013","author":"Mesko","year":"2013","journal-title":"Prostate Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0022-5347(01)65703-3","article-title":"Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy","volume":"156","author":"Bettencourt","year":"1996","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/path.6344","article-title":"Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer","volume":"264","author":"Skingen","year":"2024","journal-title":"J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1097\/01.ju.0000133655.71782.14","article-title":"Molecular and cellular pathogenesis of benign prostatic hyperplasia","volume":"172","author":"Lee","year":"2004","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.119.3.493","article-title":"Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation","volume":"119","author":"Gavrieli","year":"1992","journal-title":"J. Cell Biol."},{"key":"ref_26","unstructured":"Rode, H.D., Eisel, D., and Frost, I. (2004). Apoptosis, Cell Death and Cell Proliferation, Roche Applied Science. [3rd ed.]."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12032-016-0880-3","article-title":"IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer","volume":"34","author":"Fang","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/0008-5472.CAN-14-0992","article-title":"CSF1 receptor targeting in prostate cancer reverses macrophage mediated resistance to androgen blockade therapy","volume":"75","author":"Escamilla","year":"2015","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: Amagic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"ref_31","first-page":"217","article-title":"Chronic inflammationand cancer","volume":"16","author":"Shacter","year":"2002","journal-title":"Oncology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41568-020-0267-9","article-title":"Prostate carcinogenesis: Inflammatory storms","volume":"20","author":"Guo","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Wang, J., and Al-Lamki, R.S. (2013). Tumor necrosis factor receptor 2: Its contribution to acute cellular rejection and clear cell renal carcinoma. Bio. Med. Res. Int., 2013.","DOI":"10.1155\/2013\/821310"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T-regulatory cells: Key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e1387705","DOI":"10.1080\/2162402X.2017.1387705","article-title":"Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis","volume":"7","author":"Cari","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1158\/0008-5472.CAN-11-1156","article-title":"Targeting regulatory T cells in cancer","volume":"71","author":"Byrne","year":"2011","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sheng, Y., Li, F., and Qin, Z. (2018). TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01170"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/01.CIR.102.16.1931","article-title":"P-selectin expression on platelets determines size and stability of platelets aggregates","volume":"102","author":"Merten","year":"2000","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.thromres.2006.11.002","article-title":"Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer","volume":"120","author":"Gryko","year":"2007","journal-title":"Throm. Res."},{"key":"ref_40","first-page":"304","article-title":"Changes in platelet CD 62P expression and soluble P-selectin concentration in surgically treated colorectal carcinoma","volume":"51","author":"Osada","year":"2006","journal-title":"Adv. Med. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1590\/S1677-55382011000500008","article-title":"Endothelial inflammation and activation in benign prostatic hyperplasia and prostate cancer","volume":"37","author":"Pace","year":"2011","journal-title":"Int. Braz. J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Suzuki, K., and Matsubara, H. (2011). Recent advances in p53 research and cancer treatment. J. Biomed. Biotechnol., 2011.","DOI":"10.1155\/2011\/978312"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s10495-013-0821-y","article-title":"Proteasomal regulation of caspase-8 in cancer cell apoptosis","volume":"18","author":"Fiandalo","year":"2013","journal-title":"Apoptosis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jcb.1150","article-title":"26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer","volume":"82","author":"Shah","year":"2001","journal-title":"J. Cell Biochem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11923","DOI":"10.1074\/jbc.M508533200","article-title":"PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells","volume":"281","author":"Yeung","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pros.20706","article-title":"Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis","volume":"68","author":"Thorpe","year":"2008","journal-title":"Prostate"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1586\/erm.09.10","article-title":"DNA methylation changes in prostate cancer: Current developments and future clinical implementation","volume":"9","author":"Hoque","year":"2009","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1464-410X.2009.09167.x","article-title":"Methylated genes as potential biomarkers in prostate cancer","volume":"105","author":"Cussenot","year":"2010","journal-title":"BJU Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.prnil.2023.01.001","article-title":"DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia","volume":"11","author":"Kim","year":"2023","journal-title":"Prostate Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41391-022-00537-2","article-title":"The promising role of new molecular biomarkers in prostate cancer: From coding and non-coding genes to artificial intelligence approaches","volume":"25","author":"Scavuzzo","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_51","first-page":"631","article-title":"Impairment of autophagy may represent the molecular mechanism behind the relationship between obesity and inflammation in patients with BPH and LUTS","volume":"73","author":"Giglio","year":"2021","journal-title":"Minerva Urol. Nephrol."},{"key":"ref_52","first-page":"1","article-title":"Body composition as a determinant of the therapeutic index with androgen signaling inhibition","volume":"17","author":"Hahn","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2638\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:07Z","timestamp":1760034367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":54,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17162638"],"URL":"https:\/\/doi.org\/10.3390\/cancers17162638","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}